Squamous Cell Carcinoma (SCC)
Gene or Region: DDB2
Reference Variant: C
Mutant Variant: T
Affected Breeds: Belgian and Haflinger
Research Confidence: Preliminary - Correlates in studies with humans
Explanation of Results: sccr/sccr = homozygous for Squamous Cell Carcinoma, 80% likely affected sccr/n = heterozygous for Squamous Cell Carcinoma, carrier n/n = no variant detected
General Information for Squamous Cell Carcinoma
Squamous Cell Carcinoma is the most common cause of eye cancer in horses. It is also responsible for a large percentage of tumors throughout other parts of the equine body. A recent correlation was discovered between Squamous Cell Carcinoma (SCC) and the DDB2 genetic region. A mutation identified in that region is hypothesized to affect the protein's active role of identifying and signaling DNA regions damaged by UV light for additional “repair” protein mechanisms which attempt to restore the region and thus, prevent tumor or cancer formation. This mutation for Squamous Cell Carcinoma is currently thought an autosomal recessive disorder, thus a horse must inherit two copies (scc/scc) to be at a greatly increased risk for cancer. Studies indicate that horses with two copies of SCC (sccr/sccr) are 80% likely to be affected by Squamous Cell Carcinoma. Horses with only one allele (sccr/n) are known as carriers due to their ability to produce affected offspring.
While early studies indicate a strong correlation between the SCC mutation of DDB2 and Haflinger and Belgian horses, current studies will continue to assess the occurrence in other breeds as well.
References
Lassaline M, Cranford TL, Latimer, CA, & Bellone R. (2015) Limbal squamous cell carcinoma in Haflinger horses. Vet Ophthalmol 18(5) 404-408.
Bellone RR, Liu J, Petersen JL, Mack M, Singer-Berk M, Drögemüller C, Malvick J, Wallner B, Brem G, Penedo MC, & Lassaline M. (2017) A Missense Mutation in Damage-specific DNA Binding Protein 2 Is a Genetic Risk Factor for Limbal Squamous Cell Carcinoma in Horses. Int. J. Cancer 141(2):342-353.
More Horse Health
Equine Metabolic Syndrome / Laminitis Risk
Equine Metabolic Syndrome (EMS) is a wide-spread issue in the horse population. Primarily characterized by hyperinsulinemia (excess insulin circulating in the blood in relation to glucose levels), this metabolic disorder is often present in obese horses and ponies and can be challenging to diagnose as it can be misdiagnosed as "Cushing's" (a pituitary disfunction).
Equine Recurrent Uveitis Risk and Severity
Equine Recurrent Uveitis (ERU) is the most common cause of blindness in horses, affecting about 3-15% of the horse population worldwide. Characterized by episodes of inflammation of the middle layer of the eye, Equine Recurrent Uveitis in horses leads to the development of cataracts, glaucoma and eventually complete loss of vision.
Foal Immunodeficiency Syndrome
Foal immunodeficiency syndrome (FIS) is a failure in the development of the adaptive immune system. At 3-6 weeks of age, once the maternal antibodies begin to degrade, foals exhibit signs of anemia, diarrhea, and pneumonia. As these foals fail to respond to treatment for infections, they are humanely euthanized at a young age.
Glanzmann Thrombasthenia
Glanzmann Thrombasthenia (GT) is a blood platelet function disorder, resulting from a reduction in the platelet fibrinogen receptor protein. Clinical signs can be characterized by bleeding on the skin or from the mouth/nostril/gastrointestinal mucosas, and may include skin rashes with blood spots under the skin, nasal bleeding, gastrointestinal and gingival bleedings.